Rhenman & Partners Asset Management Ab Lowered By $1.10 Million Its Regeneron Pharmaceuticals (REGN) Holding, Everbank Financial (EVER)’s Sentiment Is 1.24

July 17, 2017 - By Marguerite Chambers

EverBank Financial Corp is a unitary savings and loan holding company. The company has market cap of $2.49 billion. The Firm is also a diversified financial services firm that provides a range of financial services and products to individuals, as well as small and mid-size business clients nationwide through channels that are connected by technology-driven, centralized platforms, which provide operating leverage throughout its business. It currently has negative earnings. It operates through three divisions: Consumer Banking, Commercial Banking and Corporate Services.

Rhenman & Partners Asset Management Ab decreased Regeneron Pharmaceuticals Inc (REGN) stake by 10.17% reported in 2016Q4 SEC filing. Rhenman & Partners Asset Management Ab sold 3,000 shares as Regeneron Pharmaceuticals Inc (REGN)’s stock rose 21.24%. The Rhenman & Partners Asset Management Ab holds 26,500 shares with $9.73M value, down from 29,500 last quarter. Regeneron Pharmaceuticals Inc now has $53.65B valuation. The stock decreased 0.03% or $0.15 on July 14, reaching $504.9. About shares traded. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has risen 17.40% since July 17, 2016 and is uptrending. It has outperformed by 0.70% the S&P500.

Timucuan Asset Management Inc Fl holds 6.24% of its portfolio in EverBank Financial Corp for 3.63 million shares. Gardner Lewis Asset Management L P owns 2.46 million shares or 3.7% of their US portfolio. Moreover, Alpine Associates Management Inc. has 3.01% invested in the company for 5.92 million shares. The Texas-based Tpg Group Holdings (Sbs) Advisors Inc. has invested 1.84% in the stock. Omni Partners Llp, a United Kingdom-based fund reported 394,122 shares.

Since January 1, 0001, it had 0 insider purchases, and 4 selling transactions for $330,798 activity.

It is down 34.51% since July 17, 2016 and is uptrending. It has outperformed by 17.81% the S&P500.

Investors sentiment increased to 1.25 in Q4 2016. Its up 0.29, from 0.96 in 2016Q3. It improved, as 48 investors sold REGN shares while 151 reduced holdings. 60 funds opened positions while 188 raised stakes. 70.27 million shares or 1.15% less from 71.09 million shares in 2016Q3 were reported. Meiji Yasuda Life Insur Com accumulated 0.16% or 2,623 shares. Commercial Bank Of America De, North Carolina-based fund reported 995,409 shares. Old Second Comml Bank Of Aurora reported 66 shares or 0.01% of all its holdings. Boston Advsr Ltd Limited Liability Company owns 7,152 shares. Atria Ltd Limited Liability Company owns 962 shares. Blackrock Fund Advsrs stated it has 2.45M shares or 0.17% of all its holdings. Moreover, Ipg Advsr Llc has 0% invested in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) for 2,650 shares. Adirondack accumulated 170 shares. Wells Fargo & Com Mn holds 0.09% or 657,177 shares in its portfolio. 13,668 were reported by Schroder Mngmt. Cap Impact Advsr Lc invested in 0.57% or 3,770 shares. Fukoku Mutual Life Insurance, a Japan-based fund reported 360 shares. Alphamark Advisors Limited Co holds 0.01% or 33 shares. Natixis holds 0.03% in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) or 9,016 shares. Bbva Compass Retail Bank invested in 10,223 shares.

Rhenman & Partners Asset Management Ab increased Aetna Inc (NYSE:AET) stake by 20,000 shares to 62,000 valued at $7.69M in 2016Q4. It also upped Intra (NASDAQ:ITCI) stake by 155,000 shares and now owns 290,000 shares. Centene Corp (NYSE:CNC) was raised too.

Among 26 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), 12 have Buy rating, 0 Sell and 14 Hold. Therefore 46% are positive. Regeneron Pharmaceuticals Inc. had 60 analyst reports since July 28, 2015 according to SRatingsIntel. The firm earned “Outperform” rating on Thursday, November 5 by RBC Capital Markets. As per Tuesday, March 8, the company rating was reinitiated by Brean Capital. The firm earned “Outperform” rating on Wednesday, August 5 by Bernstein. The stock has “Neutral” rating by Credit Suisse on Wednesday, January 20. As per Monday, June 5, the company rating was maintained by Jefferies. The rating was downgraded by Bernstein to “Market Perform” on Monday, June 26. The rating was upgraded by BTIG Research on Friday, December 16 to “Buy”. The rating was maintained by RBC Capital Markets on Friday, January 6 with “Outperform”. The stock has “Buy” rating by Canaccord Genuity on Friday, May 5. The rating was downgraded by Chardan Capital Markets to “Neutral” on Monday, August 31.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: